Innoviva, Inc. (NASDAQ:INVA) Shares Bought by Jane Street Group LLC

Jane Street Group LLC boosted its holdings in shares of Innoviva, Inc. (NASDAQ:INVA) by 46.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 136,361 shares of the biotechnology company’s stock after acquiring an additional 43,218 shares during the quarter. Jane Street Group LLC owned about 0.22% of Innoviva worth $2,633,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Innealta Capital LLC acquired a new stake in shares of Innoviva during the 2nd quarter worth about $33,000. US Bancorp DE increased its position in shares of Innoviva by 24.5% during the third quarter. US Bancorp DE now owns 2,875 shares of the biotechnology company’s stock valued at $56,000 after acquiring an additional 566 shares during the last quarter. GAMMA Investing LLC raised its stake in shares of Innoviva by 18.5% in the 3rd quarter. GAMMA Investing LLC now owns 4,119 shares of the biotechnology company’s stock valued at $80,000 after acquiring an additional 643 shares during the period. FMR LLC lifted its holdings in shares of Innoviva by 8.2% in the 3rd quarter. FMR LLC now owns 10,119 shares of the biotechnology company’s stock worth $195,000 after acquiring an additional 771 shares during the last quarter. Finally, Evergreen Capital Management LLC boosted its position in shares of Innoviva by 10.9% during the 2nd quarter. Evergreen Capital Management LLC now owns 12,321 shares of the biotechnology company’s stock worth $202,000 after purchasing an additional 1,209 shares during the period. Hedge funds and other institutional investors own 99.12% of the company’s stock.

Innoviva Stock Down 0.5 %

Innoviva stock opened at $17.84 on Friday. The company has a market capitalization of $1.12 billion, a PE ratio of 25.86 and a beta of 0.53. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.64 and a current ratio of 1.79. Innoviva, Inc. has a fifty-two week low of $14.32 and a fifty-two week high of $21.28. The firm has a 50 day moving average price of $19.31 and a 200 day moving average price of $18.51.

Innoviva (NASDAQ:INVA) last issued its quarterly earnings data on Wednesday, November 6th. The biotechnology company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.27 by ($0.25). Innoviva had a net margin of 18.31% and a return on equity of 20.84%. The firm had revenue of $89.51 million during the quarter. Research analysts expect that Innoviva, Inc. will post 0.33 earnings per share for the current year.

About Innoviva

Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.